Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3287288 | 0.82 | EPHX2 (0.70) | EPHX2HDAC8MAPK1DRD2GAA | |
| SCHEMBL464347 | 0.82 | EPHX2 (0.70) | EPHX2HDAC8MAPK1GAAKDM1A | |
| SCHEMBL461147 | 0.80 | EPHX2 (0.65) | EPHX2HDAC8MAPK1DRD2 | |
| SCHEMBL464351 | 0.79 | EPHX2 (1.00) | EPHX2HDAC8MAPK1DRD2GAA | |
| SCHEMBL13324572 | 0.78 | HDAC8 (0.42) | EPHX2HDAC8MAPK1 | |
| SCHEMBL24096619 | 0.77 | EPHX2 (0.65) | EPHX2HDAC8GAAKDM1AMAOB | |
| SCHEMBL30767948 | 0.77 | EPHX2 (0.73) | EPHX2HDAC8MAPK1GAAKDM1A | |
| SCHEMBL13324569 | 0.76 | HDAC8 (0.46) | EPHX2HDAC8MAPK1DRD2 | |
| SCHEMBL12894154 | 0.75 | HDAC8 (0.44) | EPHX2HDAC8MAPK1 | |
| SCHEMBL13324488 | 0.75 | HDAC8 (0.44) | EPHX2HDAC8MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884113-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-08 | — | — | US | disclosed |
| US-7709647-B2 | Tetrahydroquinoline cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | EPHX2 753/4885HDAC8 2230/4885MAPK1 2015/4885 |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | EPHX2 1569/4885HDAC8 2618/4885MAPK1 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.